A solitary plasmacytoma is a single tumor made of abnormal plasma cells, the immune cells that normally produce antibodies. Unlike multiple myeloma, where cancerous plasma cells spread throughout the bone marrow and cause widespread damage, a solitary plasmacytoma stays in one location. It’s rare, with an incidence of about 0.45 per 100,000 people per year for the bone type and 0.12 per 100,000 for the soft tissue type.
How It Differs From Multiple Myeloma
The key distinction is isolation. A solitary plasmacytoma is a single mass of clonal plasma cells with no signs of the systemic damage that defines multiple myeloma. To qualify as solitary plasmacytoma rather than myeloma, four things must be true: the bone marrow elsewhere in the body contains less than 10% plasma cells, and there is no anemia, no elevated calcium, no kidney damage, and no additional bone lesions. These four markers (calcium, renal insufficiency, anemia, bone lesions) are collectively known as CRAB criteria, and all must be absent.
A small amount of abnormal protein may show up in blood tests, which is expected and doesn’t change the diagnosis. What matters is that the disease hasn’t spread. If imaging reveals even one additional lesion, or if plasma cells make up 10% or more of the bone marrow, the diagnosis shifts to multiple myeloma, which requires a completely different treatment approach.
Two Types Based on Location
Solitary plasmacytoma comes in two forms, and where the tumor grows significantly affects the outlook.
Solitary bone plasmacytoma (SBP) develops inside a bone, most commonly in the spine or pelvis. It’s the more common type and carries a higher risk of eventually progressing to multiple myeloma. About 30% of patients with bone plasmacytoma remain disease-free long term, and some are considered cured.
Solitary extramedullary plasmacytoma (SEP) grows in soft tissue outside the bone, most often in the head and neck region, particularly the nasal passages, sinuses, and throat. The outlook here is considerably better: roughly 70% of patients remain disease-free at 10 years.
Who Gets It
Like multiple myeloma, solitary plasmacytoma is primarily a disease of older adults. People aged 80 and older have the highest incidence rates. The median age of onset for myeloma overall is 74, and plasmacytoma follows a similar pattern. It occurs more often in men than women.
How It’s Diagnosed
Diagnosis requires proving two things simultaneously: that the tumor exists and that the disease hasn’t spread anywhere else. A biopsy of the mass confirms it’s made of clonal plasma cells. Then comes a thorough search of the rest of the body.
Whole-body imaging is essential. PET/CT scans and whole-body MRI are both used to look for hidden lesions that would reclassify the disease as myeloma. The most important job of these scans is ruling out additional bone damage elsewhere. MRI is particularly useful for evaluating the spine and detecting early marrow involvement that might not show up on other imaging.
Blood and urine tests check for abnormal proteins. A bone marrow biopsy, usually taken from the hip, confirms that plasma cells make up less than 10% of the marrow. One specific blood test, the serum free light chain ratio, plays a dual role: it helps confirm the diagnosis and predicts future risk.
What the Free Light Chain Ratio Tells You
Nearly half of patients with solitary bone plasmacytoma (47% in one study of 116 patients) have an abnormal free light chain ratio at diagnosis. This ratio measures the balance between two types of antibody fragments in the blood, and an imbalance signals that abnormal plasma cells are producing more protein than they should be.
Patients with an abnormal ratio at diagnosis face a 44% risk of progressing to myeloma within five years, rising to 51% at 10 years. Those with a normal ratio have a much lower risk: 26% at five years and 36% at 15 years. This single test at diagnosis is one of the strongest predictors of whether the disease will stay contained or eventually spread.
Treatment With Radiation Therapy
Radiation therapy is the standard treatment. Because the disease is localized to one spot, a focused course of radiation can target the tumor directly. Typical doses range from 40 to 50 Gy, delivered over several weeks to the tumor and a small margin of surrounding tissue. For extramedullary plasmacytoma, this approach achieves excellent local control, meaning the treated tumor rarely comes back at the same site.
Surgery is sometimes used for extramedullary tumors in accessible locations, particularly in the head and neck, but radiation remains the primary approach for most patients. The treatment itself is well tolerated compared to the chemotherapy regimens used for multiple myeloma.
Risk of Progression to Myeloma
The most important thing to understand about solitary plasmacytoma is that it can eventually become multiple myeloma. This is the central concern that drives long-term monitoring. The risk varies dramatically by type: bone plasmacytoma carries a 57% chance of progressing to myeloma within five years, while extramedullary plasmacytoma has a 27% five-year progression rate.
Several factors at diagnosis help predict who is more likely to progress. An abnormal free light chain ratio is one. The size of the tumor, the presence of any detectable abnormal protein in the blood, and the results of sensitive imaging all factor in. Patients whose abnormal blood protein disappears completely after radiation tend to have a better prognosis than those whose protein levels persist.
Long-Term Monitoring
Because progression can happen years after treatment, follow-up lasts a long time. A typical schedule starts with blood tests about 6 to 8 weeks after radiation is complete, then every 3 months during the first year. After that, testing shifts to every 6 months, with imaging (usually MRI) performed at regular intervals to catch any new lesions early.
This monitoring pattern continues for at least five years. After the five-year mark, the intervals may widen to blood tests and imaging once a year, but follow-up doesn’t stop entirely. The goal at every visit is the same: catch any sign of progression to myeloma as early as possible, since early detection of myeloma opens up more treatment options. Patients with a normal free light chain ratio and complete disappearance of abnormal protein after treatment can take some reassurance from their lower risk profile, but ongoing monitoring remains important for everyone.